Badmus Biosketch

BIOGRAPHICAL SKETCH

NAME: Olufunto O. Badmus, Ph.D.

POSITION TITLE: Postdoctoral Fellow

EDUCATION/TRAINING 

PERSONAL STATEMENT:

My long-term research goal is focused on gaining the understanding of major pathways involved in the association of metabolic diseases and cardiac dysfunction. During my PhD training, I worked on the effects of steroid hormones (glucocorticoid, estrogen-progesterone) on cardio-metabolic diseases in maternal. Presently, my immediate target is to acquire additional research and practical training in the areas of metabolism and cardiovascular physiology, and also gain technical and mentoring skills that will prepare me towards building my future career as a tenure track faculty. To achieve my goals, I am pursuing my postdoctoral training in the laboratory of Dr. David E. Stec in the Department of Physiology and Biophysics at the University of Mississippi Medical Center. I am interested on how non-alcoholic fatty liver disease promotes cardiovascular disease. I am also interested in the role of bilirubin and biliverdin reductase in hepatic steatosis. The Stec lab has unique models of NAFLD which I am using to investigate the mechanisms by which cardiovascular disease develops. My project will be effectively carried out by combining my past research skills with my current training in surgery, molecular biology, and cardiovascular measurements such as echocardiographic evaluation of the heart structure and function and monitoring of blood pressure using telemetry.

Positions, Scientific Appointments, and Honors

Positions and Scientific Appointments

2016-2019:      Assistant Lecturer, Kwara State University, Malete, Kwara State, Nigeria.

2019--2021: Lecturer II, Kwara State University, Malete, Kwara State, Nigeria.

2021-present: Postdoctoral Fellow, University of Mississippi Medical Center, Jackson, MS.

Honors:

2016:               Accommodation grant award, Physiological Society of Nigeria/American Physiological Society

2016:               Best Oral Presentation- International Congress of the African Association of Physiological Sciences and Physiological Society of Nigeria

2017:               Small Grants for Theses and Dissertations, Association of African Universities

2018:               Travel grant, International Society of Hypertension

2019:               Travel grant, Physiological society, United Kingdom

2021:                Keystone Symposia Scholarship

Professional Membership:

2013-present:        Teacher’s Registration Council of Nigeria

2016-present:        Physiological Society of Nigeria

2017-present:        Physiological Society, UK (Institutional rep; 2019-2021)

2018-present:        International Society of Hypertension

2019-present:        New York Academy of Sciences

2021-present:        American Physiological Society

2022-present:        American Heart Association

Contributions to Science

Google Scholar Profile: https://scholar.google.com/citations?user=EVp35AwAAAAJ&hl=en

Effect of maternal oral contraceptive treatment on cardio-metabolic alterations induced by gestational glucocorticoid
During my PhD training, I worked on the cardio-metabolic disorders (glucose intolerance, insulin resistance, fatty liver, kidney diseases, dyslipidemia, oxidative stress) associated with gestational glucocorticoid and post- gestational combined oral contraceptive (estrogen-progestin) use. Below are the publications from my PhD work.

1. Badmus OO., and Olatunji Gestational glucocorticoid exposure disrupts glucose homeostasis that is accompanied by increased endoglin and DPP-4 activity instead of GSK-3 in rats. Environmental Toxicology and Pharmacology. 60:66-75, 2018.
2. Badmus OO, Michael OS, Rabiu S, Olatunji L.A. Glucocorticoid exposure causes disrupted glucoregulation, cardiac inflammation and elevated dipeptidyl peptidase-4 activity independent of glycogen synthase kinase-3 in female rats. Archives of Physiology and Biochemistry. 125(5): 414–422, 2019.
3. Badmus OO, Sabinari, IW, Olatunji LA. Dexamethasone increases renal free fatty acids and xanthine oxidase activity in female rats: could there be any gestational impact? Drug and Chemical Toxicology. 29:1-12,
4. Badmus OO, Njan AA, Ologe MO, Olatunji LA. Insulin resistance and depressed cardiac G6PD activity induced by glucocorticoid exposure during pregnancy are attenuated by maternal estrogen-progestin therapy. Environmental toxicology and pharmacology. 79:103423, 2020.

Mechanistic pathways involved in glucocorticoid and mineralocorticoid receptor blockade of steroid (glucocorticoid, testosterone and combined oral contraceptive) - induced cardiometabolic disorders.
I further investigated some pathways that might be involved in glucocorticoid and mineralocorticoid receptor blockade of steroid- induced cardio-metabolic disorders.

1. Usman TO, Areola ED, Badmus OO, Kim I, Olatunji A. Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities. Journal of Nutritional Biochemistry, 62, 65-75, 2018.
2. Olatunji LA, Areola ED, Badmus OO. Endoglin inhibition by sodium acetate and flutamide ameliorates cardiac defective G6PD-dependent antioxidant defense in gestational testosterone-exposed rats. Biomedicine and Pharmacotherapy, 107, 1641-1647,
3. Omolekulo TO, Areola ED, Badmus OO, Michael OS, Kim I, Olatunji LA. Inhibition of adenosine deaminase and xanthine oxidase activities by valproic acid abates glucose dysregulation and liver triglyceride accumulation independent of corticosteroids in estrogen/progestin-treated female rats. Canadian Journal of Physiology and Pharmacology, 96(11), 1092–1103,
4. Usman T, Badmus OO, Kim I, Olatunji LA. Mineralocorticoid receptor blockade attenuates disrupted glutathione-dependent antioxidant defense and elevated endoglin in the hearts of pregnant rats exposed to testosterone. Naunyn-Schmiedeberg's Archives of Pharmacology. 392(7):773-784, 2019 (Co-first author).
5. Badmus OO., and Olatunji Increased hepatic lipid accumulation caused by postpartum oral estrogen- progestin is attenuated by glucocorticoid or mineralocorticoid receptor blockade through suppressed uric acid and enhanced G6PD activity. Naunyn-Schmiedeberg's Archives of Pharmacology. 392(8):913-924, 2019.
6. Olatunji LA, Areola ED, Badmus OO, Usman TO, Olaniyi KS. Acetate causes renoprotection like androgen and mineralocorticoid receptors blockade in testosterone-exposed pregnant rats. Molecular and Cellular Biochemistry. 476(4):1861-1870,
7. Michael OS, Dibia CL, Soetan OA, Adeyanju OA, Oyewole AL, Badmus OO, Adetunji CO, Soladoye Sodium acetate prevents nicotine-induced cardiorenal dysmetabolism through uric acid/creatine kinase- dependent pathway. Life Sciences, 118127, 2020.
8. Olatunji LA, Areola ED, Usman TO, Badmus OO, Olaniyi KS. Treatment with acetate during late pregnancy protects dams against testosterone- induced renal dysfunction. 7(1): e5920, 2021.
9. Badmus OO, Areola ED, Benjamin E, Obekpa MA, Adegoke TE, Elijah OE, Imam A, Olajide OJ, Olatunji LA. Suppression of Adenosine Deaminase and Xanthine Oxidase activities by mineralocorticoid and glucocorticoid receptors blockades restore renal anti-oxidative barrier in oral contraceptive-treated dam. Renin-Angiotensin-Aldosterone System. 5:1-13, 2021.

Work from my postdoctoral fellowship

I am presently investigating how non-alcoholic fatty liver disease promotes cardiovascular disease as well as the metabolic role of bilirubin and biliverdin reductase in hepatic steatosis.

1.  Badmus OO, Kipp ZA, Bates EA, Da Silva AA, Taylor LC, Martinez GJ, Lee W, Creeden JF, Hinds TD, Jr., Stec DE. The loss of hepatic PPARα prompts fatty liver disease-induced hypertension and cardiovascular disease. Journal of Hypertension (under review), 2022.
2. Badmus OO, Hillhouse SA, Anderson CD, Hinds TD Jr., Stec DE. Molecular Mechanisms of the Metabolic Associated Fatty Liver Disease (MAFLD): Functional Analysis of Lipid Metabolism Pathways. Clinical Science, (under review), 2022.
3. Stec DE, Tiribelli C, Badmus OO, Hinds T.D, Jr. Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney 2 Diseases. Kidney360, 3(5) 945-953,

Complete List of Published Work in My Bibliography:

https://pubmed.ncbi.nlm.nih.gov/?term=olufunto+badmus